In summary, we demonstrated that in vitro TMZ screening of patient-derived GSCs can reflect treatment outcomes in IDH-wt GBM patients under the standard Stupp therapy (radiotherapy with concomitant TMZ followed by adjuvant TMZ). The gene discussed is IDH1; the disease is glioblastoma.